Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
IRVINE, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Toro Neurovascular, a company pioneering advanced catheter technologies for neurovascular intervention, today announced an exclusive distribution...
-
Ancien dirigeant de GSK et de Sanofi, M. Monteyne a supervisé le développement de Cervarix® et permis l’avancement de plusieurs traitements pionniers dans les maladies rares ; il apporte dix années...
-
Former GSK and Sanofi executive, led Cervarix® development and advanced pioneering therapies for rare diseases, decade of experience as venture capitalistStrengthens Bioxodes leadership following...
-
Le critère de sécurité a été atteint et des signes encourageants d’efficacité ont été observés lors de l’essai mené auprès de 23 patients touchés par un AVC hémorragiqueLes résultats suggèrent que...
-
Safety endpoint met, with encouraging signs of efficacy in trial with 23 patients suffering from intracerebral hemorrhage (ICH)Findings suggest BIOX-101 reduced hematoma volume and slowed...
-
Route 92 Medical filed a patent infringement suit against Balt alleging infringement of five U.S. patents protecting its Tenzing delivery technology.
-
Brain Injury Association of America honors Centre for Neuro Skills' Dr. Mark Ashley as 2025 Luminary of the Year for contributions in brain injury field
-
Omniscient and The Jacobs Institute launch Connectomics Innovation Program to advance stroke recovery and neurologic care with AI-enabled software.
-
Joint research program targets new treatments for life-threatening complication of brain hemorrhage An international discovery collaboration is harnessing AI-powered drug discovery to develop a...
-
Belleville, Illinois, June 27, 2025 (GLOBE NEWSWIRE) -- In recognition of Men’s Health Month, Allsup, a leading provider of Social Security Disability Insurance (SSDI) representation, return to work...